Biotech Values

[DewDiligence]

(MNTA)—CHRS halts development on Humira FoB for time being due to IPR loss on ABBV’s ‘619 formulation patent (#msg-134452711). This was confirmed on CHRS’ 3Q17 CC this afternoon.

CHRS’ new guidance for the timing its Humira-FoB US launch is late 2022—i.e. around the time of AMGN’s Jan 2023 guaranteed launch date in AMGN’s recent litigation settlement with ABBV (#msg-134970085).

MNTA too is backing off its prior assertion of being able to circumvent ABBV’s Humira-formulation patents and hinted on its own 3Q17 CC last week that the US launch of M923 probably won’t happen until 2022.